Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage

被引：8
作者：
Alffenaar, Jan-Willem C. [1 ]
van der Elst, Kim C. M. [1 ]
Uges, Donald R. A. [1 ]
Kosterink, Jos G. W. [1 ]
Daenen, Simon M. G. J. [2 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hosp & Clin Pharm, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Haematol, NL-9700 RB Groningen, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 68卷 / 03期
关键词：
PHARMACOKINETICS; GENOTYPE;
D O I：
10.1111/j.1365-2125.2009.03464.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：462 / 463
页数：2
相关论文
共 9 条
[1]   High voriconazole trough levels in relation to hepatic function: how to adjust the dosage? [J].
Alffenaar, Jan-Willem C. ;
de Vos, Tessa ;
Uges, Donald R. A. ;
Daenen, Simon M. G. J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 67 (02) :262-263
[2]   Optimal Prevention of Seizures Induced by High-Dose Busulfan [J].
Eberly, Andrea L. ;
Anderson, Gail D. ;
Bubalo, Joseph S. ;
McCune, Jeannine S. .
PHARMACOTHERAPY, 2008, 28 (12) :1502-1510
[3]   Breakthrough Candida infections in patients receiving voriconazole [J].
Gerzenshtein, L ;
Patel, SM ;
Scarsi, KK ;
Postelnick, MJ ;
Flaherty, JP .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (7-8) :1342-1345
[4]   Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration [J].
Purkins, L ;
Wood, N ;
Ghahramani, P ;
Love, ER ;
Eve, MD ;
Fielding, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 :37-44
[5]   Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients [J].
Trifilio, Steve ;
Pennick, Gennethel ;
Pi, Judy ;
Zook, Jennifer ;
Golf, Mary ;
Kaniecki, Kimberley ;
Singhal, Seema ;
Williams, Stephanie ;
Winter, Jane ;
Tallman, Martin ;
Gordon, Leo ;
Frankfurt, Olga ;
Evens, Andrew ;
Mehta, Jayesh .
CANCER, 2007, 109 (08) :1532-1535
[6]   Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America [J].
Walsh, Thomas J. ;
Anaissie, Elias J. ;
Denning, David W. ;
Herbrecht, Raoul ;
Kontoyiannis, Dimitrios P. ;
Marr, Kieren A. ;
Morrison, Vicki A. ;
Segal, Brahm H. ;
Steinbach, William J. ;
Stevens, David A. ;
van Burik, Jo-Anne ;
Wingard, John R. ;
Patterson, Thomas F. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (03) :327-360
[7]   The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers [J].
Wang, Guo ;
Lei, He-Ping ;
Li, Zhi ;
Tan, Zhi-Rong ;
Guo, Dong ;
Fan, Lan ;
Chen, Yao ;
Hu, Dong-Li ;
Wang, Dan ;
Zhou, Hong-Hao .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (03) :281-285
[8]   CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole [J].
Weiss, Johanna ;
ten Hoevel, Magdalena Maria ;
Burhenne, Juergen ;
Walter-Sack, Ingeborg ;
Hoffmann, Michael Marcus ;
Rengelshausen, Jens ;
Haefeli, Walter E. ;
Mikus, Gerd .
JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 49 (02) :196-204
[9]   Drug interactions between chemotherapeutic regimens and antiepileptics [J].
Yi-Lwern, Kevin ;
Chui, Wai Keung ;
Chan, Alexandre .
CLINICAL THERAPEUTICS, 2008, 30 (08) :1385-1407
1